GeNeuro Announces Enrollment of First Patients at Five Swiss Centers in First Long COVID Personalized Medicine Clinical Trial Evaluating Temelimab

GeNeuro Announces Enrollment of First Patients at Five Swiss Centers in First Long COVID Personalized Medicine Clinical Trial Evaluating Temelimab

Geneva, Switzerland–(BUSINESS WIRE)–Regulatory news: GeNeuro (Euronext Paris: CH0308403085 – GNRO) (Paris:GNRO), a biopharmaceutical company specializing in stopping the causal factors behind the progression of neurodegenerative and autoimmune diseases such as multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS) and post-acute sequelae of COVID-19 (PASC, long-COVID or post-COVID), today announced the enrollment of the first patients in …

GeNeuro Announces Enrollment of First Patients at Five Swiss Centers in First Long COVID Personalized Medicine Clinical Trial Evaluating Temelimab Read More »